Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ebola breakthrough? new trial aims to stop virus after exposure

NCT ID NCT06841614

Prevention Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a vaccine plus an antibody drug right after high-risk Ebola contact can prevent the disease better than the vaccine alone. About 160 people who have had close contact with an Ebola patient (like touching body fluids or a dead body) will be randomly assigned to one of two groups. The goal is to see which approach lowers the chance of getting sick.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Last high-risk contact within the last 5 days * No sign or symptoms of EVD * Signed and dated informed consent from participants over the age of majority to participate in the trial or from a representative of parental authority for minor participants. Non-inclusion criteria * History of vaccination with Ervebo or any other EVD vaccine within the last 5 years (self-reported by the participant) * History of confirmed EVD within the last 5 years (self-reported by the participant) * Hypersensitivity to any of the experimental medical products (IMP) or their excipients (self-reported by the participant) * Participation in another therapeutic or vaccine trial for EVD * Any other reason that, at the investigator's discretion, could compromise the participant's safety and cooperation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ebola virus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ebola hemorrhagic fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ebola virus disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guinea Centre for Research and Training in Infectious Diseases (CERFIG)

    Conakry, Guinea

  • National Institute for Biomedical Research (INRB)

    Kinshasa, Democratic Republic of the Congo

  • National Public Health Institute of Liberia

    Monrovia, Liberia

  • University of Sierra Leone College of Medicine and Allied Health Sciences

    Freetown, Sierra Leone

More trials for these conditions

Other studies related to the condition(s) this trial covers.